Loading
A phase 2/3 trial of PM8002 and Nivolumab in gastric & gastro-oesophageal junction cancer, run by Bristol-Myers Squibb, now recruiting.
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) is a phase 2/3 interventional study registered as NCT07221149 by Bristol-Myers Squibb, with 690 participants planned, started 2026-03-13 and due to reach its primary completion in 2030-11-08. Interventions recorded: Pumitamig, Folfox, Capox and Nivolumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors and the tag pipeline.
Shares PM8002, Bristol Myers Squibb, Nivolumab and the tag pipeline.
Shares PM8002, BioNTech, Bristol Myers Squibb and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/